TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11509937
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg intravenous immunoglobulin
Study: 11509937
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg intravenous immunoglobulin
Study: 22957483
Drug: tongue protector
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: tongue protector and 0.5 ml AV at 70% three times a day
Study: 22957483
Drug: tongue protector
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: tongue protector and 0.5 ml placebo three times a day
Study: 21226818
Drug: Dapagliflozin (2.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (2.5-50 mg in SAD study; 2.5-20 mg QD for 14 days in MAD study)
Study: 29426388
Drug: Home-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based occupational therapy intervention
Study: 23579002
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB) supplementation (0.3 g/kg body mass)
Study: 23573950
Drug: Givinostat 50
Normalized name: givinostat
DrugBank: Givinostat (DB12645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givinostat 50 mg/d
Study: 23573950
Drug: Givinostat 100
Normalized name: givinostat
DrugBank: Givinostat (DB12645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givinostat 100 mg/d
Study: 16834644
Drug: Propiverine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 20 mg once daily
Study: 7933523
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627) administered intravenously at daily doses of 17-37.5 mg/kg for 4-7 consecutive days
Study: 7933523
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627) at a dose of 6 mg/kg
Study: 7933523
Drug: Biapenem (L-627)
Normalized name: L
DrugBank: Biapenem (DB13028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biapenem (L-627) at a dose of 12 mg/kg
Study: 3063133
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg/kg bolus, then 0.2 mg/kg/min infusion for 10 min)
Study: 3063133
Drug: Diazepam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3 mg/kg bolus)
Study: 3063133
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg/kg bolus)
Study: 31125155
Drug: NTP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTP treatment
Study: 30073253
Drug: Topical dornase
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical dornase alfa (5 drops each ear twice a day for 7 days)
Study: 30073253
Drug: Ofloxacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (5 drops each ear twice a day for 7 days)
Study: 27007392
Drug: CoQ (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ (200 mg)
Study: 27007392
Drug: Both supplements
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both supplements (n-3 fatty acids and CoQ)
Study: 24802626
Drug: Magnet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnet group (ICD therapy suspended with a magnet)
Study: 24802626
Drug: Off group
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off group (ICD therapy programmed off)
Study: 22374377
Drug: S-Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Ketamine (0.5 mg/kg i.m. bolus followed by 2 μg/kg/min i.v. continuous infusion for 12 h)
Study: 18565884
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with 6 months of combined androgen suppression therapy (AST)
Study: 18565884
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) with less than 6 months of combined androgen suppression therapy (AST)
Study: 16043985
Drug: RDP58 100
Normalized name: RDP58
DrugBank: RDP58 (DB06566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDP58 100 mg
Study: 16043985
Drug: RDP58 200
Normalized name: RDP58
DrugBank: RDP58 (DB06566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDP58 200 mg
Study: 16043985
Drug: RDP58 300
Normalized name: RDP58
DrugBank: RDP58 (DB06566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDP58 300 mg
Study: 12502122
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil topical cream applied once daily for 1, 2, or 4 weeks
Study: 12502122
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil topical cream
Study: 7718459
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (300 mg) daily for 4 months
Study: 7718459
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet) daily for 4 months
Study: 2381302
Drug: Dicalcium phosphate
Normalized name: DICALCIUM PHOSPHATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicalcium phosphate (129 mmol) and glucose (500 ml/10% sol)
Study: 30152390
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (prednisolone)
Study: 23377514
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2%/BPO 2.5% gel
Study: 18098001
Drug: Methamphetamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine treatment approaches
Study: 15606443
Drug: Trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 200 mg given twice daily for 5 days
Study: 12089223
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 oral topotecan with 1,000 mg GF120918
Study: 12089223
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 intravenous topotecan with 1,000 mg GF120918
Study: 12089223
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 oral topotecan without GF120918
Study: 12089223
Drug: 1.0 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/m2 intravenous topotecan without GF120918
Study: 9453518
Drug: Tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-type plasminogen activator with heparin estimated by aPTT
Study: 7822520
Drug: terbinafine, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine, 250 mg/day
Study: 7822520
Drug: griseofulvin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: griseofulvin, 500 mg/day
Study: 30057104
Drug: High-dose PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PPI (40 mg twice-daily)
Study: 30057104
Drug: Low-dose PPI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PPI (20 mg once-daily)
Study: 30057104
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg per day in the UK, 325 mg per day in Canada)
Study: 30057104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose PPI and aspirin
Study: 30057104
Drug: Low-dose PPI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PPI without aspirin
Study: 25759177
Drug: Home-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based oral care training programme
Study: 25759177
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care education
Study: 22354743
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplementation (20,000 IU weekly)
Study: 18030230
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg daily for 12 months)
Study: 18030230
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg daily for 12 months) + Vitamin D2 (50,000 IU monthly for 6 months)
Study: 17373638
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg qd
Study: 12802214
Drug: Pharmaceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatment for chronic illnesses
Study: 12802214
Drug: Pharmaceutical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical treatment
Study: 10778797
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (water) at 30 degrees/s
Study: 10778797
Drug: Dry land
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry land therapy at 30 degrees/s
Study: 10778797
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (water) at 45 degrees/s
Study: 10778797
Drug: Dry land
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry land therapy at 45 degrees/s
Study: 30105847
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal hydroquinone
Study: 25379688
Drug: Active supplement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active supplement (500 mg olive leaf extract, 100 mg green coffee bean extract, 150 mg beet powder)
Study: 22546837
Drug: Docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (T) 75 mg/m² on day 1 of a 21-day cycle for six cycles
Study: 15138163
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus daclizumab (1 mg/kg)
Study: 15138163
Drug: Corticosteroids (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (2 mg/kg)
Study: 15257932
Drug: Autologous transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous transplantation or maintenance chemotherapy (given to 84 patients without a sibling donor)
Study: 15257932
Drug: Autologous transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous transplantation or maintenance chemotherapy (without donor)
Study: 10333984
Drug: Befloxatone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone (up to 160 mg single dose or 80 mg/day for 7 days)
Study: 10333984
Drug: Befloxatone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone (up to 20 mg once daily)
Study: 10333984
Drug: Befloxatone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone (10 mg dose)
Study: 10333984
Drug: Befloxatone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befloxatone (various doses)
Study: 2654849
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (7.9 +/- 0.4 mg/kg)
Study: 19148629
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Study: 19148629
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Study: 17529899
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice a day
Study: 17529899
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice a day
Study: 15061265
Drug: Dopaminergic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic and non-dopaminergic treatment (off-medication)
Study: 9493577
Drug: 1 l
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 l gelatin‐based plasma substitute (Gelofusine)
Study: 8043455
Drug: Vinblastine slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine slow infusion
Study: 8043455
Drug: Vinblastine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine bolus injection
Study: 1818430
Drug: Klion ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Klion ointment
Study: 76857
Drug: Injection/compression sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection/compression sclerotherapy
Study: 21806517
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or four counselling sessions involving cognitive behaviour therapy and motivational interviewing techniques to manage methamphetamine use.
Study: 18257156
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy with sparfloxacine and vibromagnetolaser therapy (VMLG‐10 unit)
Study: 18257156
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy with sparfloxacine and 10 sessions of manual massage
Study: 18257156
Drug: Vibromagnetolaser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibromagnetolaser therapy (VMLG‐10 unit)
Study: 11187872
Drug: High-dose FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FVIII regimen
Study: 11187872
Drug: Low-dose FVIII
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FVIII regimen
Study: 11187872
Drug: Bypass therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bypass therapy (on demand)
Study: 29770528
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for age, sex, and medication received
Study: 24326421
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 125 mg/wk) + Finasteride (5 mg/day)
Study: 24326421
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 125 mg/wk)
Study: 2201266
Drug: Artificial surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial surfactant treatment
Study: 19152520
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 5-aminolevulinic acid (ALA)
Study: 19152520
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (PDT)
Study: 16201049
Drug: Domestic fixed-dose
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic fixed-dose combinations (rifampicin 120 mg, isoniazid 80 mg, pyrazinamide 250 mg for 2 months; rifampicin 300 mg, isoniazid 150 mg for 4 months)
Study: 16201049
Drug: Domestic fixed-dose
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic fixed-dose combinations
Study: 11098962
Drug: Midazolam (0.1-0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1-0.35 mg/kg/hr)
Study: 11098962
Drug: 2% Propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Propofol (1.5-6 mg/kg/hr)
Study: 9031577
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration during a 4-week double-blind and placebo-controlled study with a 2-week single-blind placebo lead-in period.
Study: 8341050
Drug: Individually focused
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually focused cognitive behavioral (CB) treatment
Study: 8341050
Drug: Relationship enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relationship enhancement (RE) of brief cognitive behavioral treatments
Study: 26038078
Drug: Light buccopalatal
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light buccopalatal jiggling forces (25 g)
Study: 26038078
Drug: Heavy buccopalatal
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy buccopalatal jiggling forces (225 g)
Study: 26038078
Drug: Continuous buccal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous buccal forces (positive control)
Study: 12873621
Drug: THC infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC infusion and marijuana smoking
Study: 10416877
Drug: Progestational drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestational drugs
Study: 6962421
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus B.C.G.
Study: 27741414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (systemic antibiotics only)
Study: 26485385
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of lidocaine with 1 mg of morphine (MLA group)
Study: 26485385
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of lidocaine alone (LA group)
Study: 23569029
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg Uceris®
Study: 23569029
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg Entocort® EC
Study: 22156352
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate 30 g/day for fifteen days
Study: 22156352
Drug: White chocolate
Normalized name: chocolate allergenic extract
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White chocolate 25 g/day for fifteen days (Control)
Study: 19827910
Drug: Pioglitazone/metformin fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone/metformin fixed-dose combination (FDC) therapy
Study: 19827910
Drug: Pioglitazone/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone/metformin FDC therapy
Study: 6313376
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg daily for 4 weeks
Study: 6313376
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg daily
Study: 29352654
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Control (CON)
Study: 22577905
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in obese group (BMI ≥ 27.5 kg/m(2))
Study: 22577905
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, or 11 mg) in non-obese group (BMI <27.5 kg/m(2))
Study: 20795382
Drug: Bubo-M vaccine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubo-M vaccine
Study: 20795382
Drug: Bubo-M vaccine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubo-M vaccine and hepatitis B vaccine
Study: 16238909
Drug: Lopinavir 400
Normalized name: LOPINAVIR 400MG/RITONAVIR 100MG/5ML SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir 400 mg boosted with ritonavir 100 mg twice daily
Study: 29792081
Drug: Researcher-developed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Researcher-developed treatment (small-group tutoring for 30 to 45 minutes for an average of 68 lessons, mean hours of instruction = 44.4, SD = 11.2)
Study: 22878802
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents
Study: 17532398
Drug: Adenosine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (1.5 mg/kg)
Study: 15466673
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg intramuscular) every 2 weeks for 1 month
Study: 15466673
Drug: Lupron (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron (7.5 mg intramuscularly) every 4 weeks for 3 months
Study: 7910724
Drug: Ketoconazole +
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole + Sucralfate (1.0 g) administered simultaneously with 240 ml of water
Study: 7910724
Drug: Ketoconazole administered
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole administered 2 hours after Sucralfate (1.0 g)
Study: 7910724
Drug: Ketoconazole administered
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole administered with 240 ml of water
Study: 3582724
Drug: 1% hydrocortisone/10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hydrocortisone/10% urea cream
Study: 23078631
Drug: Idrabiotaparinux (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrabiotaparinux (3.0 mg)
Study: 16934051
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg daily for 4 days
Study: 10776362
Drug: Step Test
Normalized name: SureStep Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step Test Exercise Prescription (STEP)
Study: 10776362
Drug: Counseling using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling using the American College of Sports Medicine guidelines (control)
Study: 9176463
Drug: Discontinuous-long protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous-long protocol (n = 68) with GnRH agonist administered from luteal phase until cycle day 7, followed by pure FSH administration.
Study: 9176463
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (n = 69) with GnRH agonist administered until the day before hCG administration.